Evidence map›Paper›PMID 42399565›Full record

ArticleActa neuropathologica2026

Mutation-specific neuropathologic signatures in MAPT-associated frontotemporal lobar degeneration.

Marika Bogdani, Vaishnavi S Jadhav, Brian C Kraemer, Thomas J Grabowski, Suman Jayadev, Kimiko Domoto-Reilly, Nicole F Liachko, Thomas D Bird, C Dirk Keene, Caitlin S Latimer

Abstract read
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marika BogdaniDepartment of Laboratory Medicine and Pathology, University of Washington, 325 9th Ave, Seattle, WA, 98104, USA.
Vaishnavi S JadhavGeriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.
Brian C KraemerGeriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.
Thomas J GrabowskiDepartment of Neurology, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Suman JayadevDepartment of Neurology, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Kimiko Domoto-ReillyDepartment of Neurology, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA, 98195, USA.
Nicole F LiachkoGeriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.
Thomas D BirdGeriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, University of Washington, 325 9th Ave, Seattle, WA, 98104, USA.
Caitlin S LatimerDepartment of Laboratory Medicine and Pathology, University of Washington, 325 9th Ave, Seattle, WA, 98104, USA. caitlinl@uw.edu.ORCID https://orcid.org/0000-0003-3727-4278

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Paul K Crane, Andrea Z. LaCroix · 2021 to 2026
$80.4M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
TDP-43 in Alzheimer's diseaseR01AG066729 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI LIACHKO, NICOLE FARON · 2021 to 2025
$2.6M
SPOP drives neurodegenerative tauopathyRF1AG078374 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI KRAEMER, BRIAN C. · 2023 to 2023
$1.8M
Novel Mechanisms of tau and TDP-43 synergy in Alzheimer's diseaseR01AG090551 · NIA · UNIVERSITY OF WASHINGTON · PI Caitlin Shannon Latimer · 2025 to 2026
$1.5M
NIA NIH HHS P30 AG066509NIA NIH HHS U19 AG066567NIH HHS P30 AG066509NIH HHS R01AG066729NIH HHS R01AG090551NIH HHS RF1AG078374NIH HHS U19AG063911NIH HHS U19 AG066567U.S. Department of Defense W81XWH-21-S-TBIPH2U.S. Department of Veterans Affairs I01BX005762U.S. Department of Veterans Affairs IK6BX006467
6 · The paper itself

Abstract

Autosomal-dominant frontotemporal lobar degeneration with tau pathology (FTLD-tau) is caused by pathogenic variants in the MAPT gene. Although abnormal tau aggregation is a shared endpoint, MAPT mutations produce distinct cellular phenotypes and regional patterns of tau deposition, the mutation specificity and familial consistency of which remain poorly defined. We performed a systematic neuropathologic and transcriptomic analysis of brains from clinically characterized families carrying MAPT V337M, P301L, or L284L mutations. Multiple affected members per family were examined, with interfamily comparisons for P301L. Quantitative assessment of regional tau burden, cellular morphology, and co-pathologies revealed distinct, mutation-specific signatures. The V337M mutation was characterized by predominantly neuronal tau pathology with vesicular pretangles, scattered neurofibrillary tangles, and fine neurites, with minimal glial involvement. P301L exhibited prominent astrocytic tau pathology, including globular and proximal inclusions, accompanied by neuronal pretangles. L284L produced extensive oligodendroglial tau pathology with thick fibrillar coiled bodies in gray and white matter. Additional distinguishing features included hippocampal sclerosis and TDP-43 pathology in V337M; severe cortical neuronal loss and dentate fascia tau in P301L; and extensive white matter and brainstem tau, including ventral pontine neurons, in L284L. These morphologic profiles were conserved within families and, for P301L, across unrelated families. Transcriptomic analyses suggested mutation-linked expression changes concordant with cellular pathology. These findings define reproducible, mutation-specific neuropathologic and molecular signatures of MAPT-associated FTLD-tau, emphasizing the importance of genotype-driven stratification in studies of tauopathy pathogenesis.

Indexed as

Frontotemporal Dementiatau ProteinsAgedApolipoproteins EFemaleGenotypeHumansMaleMiddle AgedMutationNeuronsProtein IsoformsApoE protein, humanApolipoproteins EMAPT protein, humanProtein Isoformstau ProteinsFrontotemporal lobar degeneration with tauopathy (FTLD-tau)MAPTNeurodegenerationNeuropathologyTau

Identifiers

PMID42399565
PMCPMC13331856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.